Novaremed AG
PrivateLast Round
PIPE
Jan 28, 2021
Company Overview
Novaremed AG is a biopharmaceutical company that develops small bio-molecule drugs for the treatment of neuropathic pain.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Novaremed AG Comparables
Compare Novaremed AG with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Plumeria Therapeutics, Inc. | 85% | |
| NeuroFront Therapeutics | 84% | |
| 上海赛默罗生物科技有限公司 | 83% | |
Novaremed AG Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| PIPE | Jan 28, 2021 | ||||
| VC Round | Sep 15, 2020 | ||||
| VC Round | Sep 2, 2019 | ||||
| VC Round | Aug 23, 2018 | ||||
| VC Round | Apr 19, 2018 |
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 28, 2021
$50M raised from Gemny.
- Sep 2, 2019
Raised $2.63M in a VC Round.
Novaremed AG Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Novaremed AG's valuation, stock price, and market status.